Page 75 - MemoriaEHD-Eng

www.ciberehd.org

It is a mixed research group formed by hepatologists, surgeons and basic resear-
Highlights
chers specializing in biomedicine, focusing investigation in liver diseases.

The main lines of research are: liver transplant, hepatocellular carcinoma and

acute and chronic hepatocellular damage.

Some of the research activity in 2013 has been centered in multicentric studies:

• “CLIF: Acute on chronic liver failure in cirrhosis”

• “Inhibición of mTOR via with everolimus in patients who undergo liver transplan-
tion due to hepatocellular carcinoma and its impact on tumor recurrence”.

• “ Long-term diabetes in liver transplant patients”

• “A randomized double-blind trial on patients with advanced hepatocellular carci-
noma to assess the efficacy of sorafenib beyond radiological progression”.

• “The value of artificial neural network in donor-receptor matching for liver trans-

plantation.

In addition, a number a trial are in progress:

• “A phase III, randomized, double-blind, placebo- controlled study of everolimus

plus best supportive care in patients with advanced hepatocellular carcinoma

that progressed during or after sorafenib treatment or who are intolerant of
sorafenib”

• “A randomized, double blind, multicenter phase III study of regorafenib in pa-

tients with hepatocellular carcinoma (HCC) after Sorafenib”.

• “Open multicentric randomized and controlled study to evaluate the eficacy and

safety of ELAD in patients with acute alcoholic hepatitis (AAH) after failure of
treatment with steroids”.

• “Molecular predictors of response to Sorafenib adjuvant therapy after resection

of hepatocellular carcinoma”

• “ Observational study of reduced immunosuppression in liver transplant pa-

tients”.

• “Use of Telaprevir y Boceprevir registry in real clinical practice”

• “A clinical model to predict acute cellular rejection after liver transplantation”

13
20
T
OR
P
RE
L
A
NU
N
A
D /
H
E
ER
IB
C

75